Jan 16, 2020 / 07:00PM GMT
Federica Lussana;JPMorgan;Analyst -
Good morning, everyone. My name is Federica Lussana, and I'm part of the Healthcare Investment Banking team at JPMorgan. It is my pleasure to introduce you to our next presenting company, Karuna Therapeutics. And the speaker is Steve Paul, Chairman of the Board, President and Chief Executive Officer.
Just as a kind of reminder, after this session, we are going to have a breakout session in the Yorkshire room. Thank you.
Steven M. Paul - Karuna Therapeutics, Inc. - CEO, President & Chairman
Okay. Well, thank you. It's a great pleasure to tell you about Karuna Therapeutics. I actually appreciate everybody being here, the last day of the conference. Fantastic.
So let me begin with a -- Karuna at a glance. What are we trying to do? We're developing a novel mechanism of action therapeutic drug targeting CNS indications, representing large and underserved patient populations. And you'll see that specifically in a few minutes.
We recently announced some very encouraging Phase
Karuna Therapeutics Inc at JPMorgan Healthcare Conference Transcript
Jan 17, 2020
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers